This site is intended for healthcare professionals
Drug news

Encenicline (FRM 6124) fails in two Phase III trials to treat cognitive impairment with schizophrenia- Forum Pharma

Read time: 1 mins
Last updated:30th Mar 2016
Published:30th Mar 2016
Source: Pharmawand

Topline results were announced by Forum Pharma of two Phase III trials in patients with cognitive impairment with schizophrenia and they demonstrated for encenicline (FRM 6124) a favourable safety and tolerability profile but neither study met its co primary endpoint based on cognitive function and patient function. An unexpected placebo response was observed in both trials.The Company will implement significant restructuring.

Comment: The FDA still has the Alzheimer's program for encenicline on hold after a number of patients taking the drug reported severe gastrointestinal events last year.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.